Methods : Adults with CLD and evidence of meibomian gland obstruction (n=67) were randomized (1:1) to AZR 0.5% (n=34) or vehicle (n=33) applied twice weekly at bedtime for 3 months in a Phase 2, multi-center, single-masked parallel-group study (NCT05548491). Key efficacy endpoints ...
Marc Gleeson, CEO of Azura, sat down with David Hutton, Managing Editor at Ophthalmology Times to discuss the recent positive results from the Phase 2 clinical trial of AZR-MD-001 in patients with contact lens discomfort. Video Transcript Editor's note ...
Methods : Adults with CLD and evidence of meibomian gland obstruction (n=67) were randomized (1:1) to AZR 0.5% ophthalmic ointment (n=34) or vehicle (n=33), applied to the lower lid twice weekly before bedtime for 3 months in a Phase 2, multi-center, double-masked parallel-group ...
(Contact Lens Dry Eye Questionnaire-8 >12) and evidence of meibomian gland obstruction (Meibomian Gland Secretion Score [MGS] <12) were randomized (1:1) to AZR 0.5% (n=34) or vehicle (n=33) applied to the lower eyelid twice weekly for 3 months in Phase 2, multicenter, double-masked...
Methods : Adults with CLD and evidence of meibomian gland obstruction (n=67) were randomized (1:1) to AZR 0.5% ophthalmic ointment (n=34) or vehicle (n=33), applied to the lower lid twice weekly before bedtime for 3 months in a Phase 2, multi-center, double-masked parallel-group ...
Methods : This Phase 2 prospective, multi-center, randomized, double-masked, vehicle-controlled, parallel-design trial included 67 participants aged 18 and older with CLD (Contact Lens Dry Eye Questionnaire-8 >12) and evidence of meibomian gland obstruction (Meibomian Gland Secretion Score <12) ...
Methods : Adults with mild to moderate MGD (n=245) were randomized (1:1:1) to AZR 0.5% (n=82) or 1.0% (n=83), or vehicle (n=80) applied by the subjects to the lower eyelid, twice weekly at bedtime for 6 months in a Phase 2, prospective, double-masked trial (NCT03652051)....